What top creators are saying about Cassava Sciences, Inc.(SAVA)

The speaker is bearish, expressing deep skepticism towards the company's management and scientific claims, implying he was short the stock.

Mentioned as a negative comparison to the ATYR trade, with the speaker stating the ATYR situation is 'in some ways... worse than cassava,' which reinforces their bearish conviction on ATYR.

Cited as a successful past example of a 'binary event' short trade, similar to the speaker's current thesis on ATYR Pharma. The commentary is historical.

Described with extremely high conviction as a 'true, once in a lifetime, generational opportunity' and a stock where the speaker has immense certainty after deep research.

Highlighted for its own data integrity controversies, with a statistician from the company also being involved with Capricor's trial data, raising a red flag.

The speaker describes the company as a 'true once in a lifetime generational opportunity' in the small biotech space.

The analyst is bearish, grouping it with other companies he is skeptical of. The recommended strategy is to 'Stay short', indicating a belief that the stock is overvalued and will eventually decline.

Referenced as a past successful short position that the speaker considered a 'fraud from the start', used to establish a track record in identifying flawed biotech companies.